Literature DB >> 10485918

The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor.

J K Doherty1, C Bond, A Jardim, J P Adelman, G M Clinton.   

Abstract

HER-2/neu (erbB-2) encodes an 185-kDa orphan receptor tyrosine kinase that is constitutively active as a dimer and displays potent oncogenic activity when overexpressed. Here we describe a secreted protein of approximately 68 kDa, designated herstatin, as the product of an alternative HER-2 transcript that retains intron 8. This alternative transcript specifies 340 residues identical to subdomains I and II from the extracellular domain of p185HER-2 followed by a unique C-terminal sequence of 79 aa encoded by intron 8. The recombinant product of the alternative transcript specifically binds to HER-2-transfected cells with a K(D) of approximately 14 nM and was chemically crosslinked to p185HER-2, whereas the intron encoded sequence alone also binds with high affinity to transfected cells and associates with p185 solubilized from cell extracts. The herstatin mRNA is expressed in normal human fetal kidney and liver, but is at reduced levels relative to p185HER-2 mRNA in carcinoma cells that contain an amplified HER-2 gene. Herstatin appears to be an inhibitor of p185HER-2, because it disrupts dimers, reduces tyrosine phosphorylation of p185, and inhibits the anchorage-independent growth of transformed cells that overexpress HER-2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485918      PMCID: PMC17975          DOI: 10.1073/pnas.96.19.10869

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells.

Authors:  Y Z Lin; G M Clinton
Journal:  Oncogene       Date:  1991-04       Impact factor: 9.867

2.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

Authors:  R M Hudziak; J Schlessinger; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 3.  The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.

Authors:  W C Dougall; X Qian; N C Peterson; M J Miller; A Samanta; M I Greene
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

Review 4.  A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling.

Authors:  K L Carraway; L C Cantley
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation.

Authors:  M Tal; C R King; M H Kraus; A Ullrich; J Schlessinger; D Givol
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

6.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

7.  EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling.

Authors:  P P Di Fiore; O Segatto; W G Taylor; S A Aaronson; J H Pierce
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

8.  A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.

Authors:  G K Scott; R Robles; J W Park; P A Montgomery; J Daniel; W E Holmes; J Lee; G A Keller; W L Li; B M Fendly
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

9.  The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.

Authors:  F Lonardo; E Di Marco; C R King; J H Pierce; O Segatto; S A Aaronson; P P Di Fiore
Journal:  New Biol       Date:  1990-11

Review 10.  The biology of erbB-2/neu/HER-2 and its role in cancer.

Authors:  N E Hynes; D F Stern
Journal:  Biochim Biophys Acta       Date:  1994-12-30
View more
  30 in total

1.  Primary trastuzumab resistance: new tricks for an old drug.

Authors:  Jason A Wilken; Nita J Maihle
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

2.  The peptide derived from erbB2 auto-inhibitor herstatin shared in the same epitope and function with functional antibody 2C4.

Authors:  Ming Lv; Chunxia Qiao; Nan Jiang; Xinying Li; Ming Yu; Chunmei Hou; Yan Li; Jiannan Feng; Beifen Shen
Journal:  Mol Biotechnol       Date:  2012-06       Impact factor: 2.695

3.  The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.

Authors:  T Kumagai; J G Davis; T Horie; D M O'Rourke; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 4.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

Review 5.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

Review 6.  Signaling from novel splice variants of hormone receptors in cancer.

Authors:  Wei-Qun Ding; Laurence J Miller
Journal:  Int J Gastrointest Cancer       Date:  2002

7.  Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.

Authors:  Motoko Takahashi; Yoshihiro Hasegawa; Yoshitaka Ikeda; Yoshinao Wada; Michiko Tajiri; Shigeru Ariki; Rina Takamiya; Chiaki Nishitani; Motoko Araki; Yoshiki Yamaguchi; Naoyuki Taniguchi; Yoshio Kuroki
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

8.  Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field.

Authors:  Fernanda Ledda; Gustavo Paratcha
Journal:  Biomark Insights       Date:  2007-02-14

Review 9.  Mechanisms of ErbB receptor negative regulation and relevance in cancer.

Authors:  William H D Fry; Lakmal Kotelawala; Colleen Sweeney; Kermit L Carraway
Journal:  Exp Cell Res       Date:  2008-07-31       Impact factor: 3.905

10.  A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.

Authors:  Triantafyllia Koletsa; Ioannis Kostopoulos; Elpida Charalambous; Barbara Christoforidou; Eleni Nenopoulou; Vassiliki Kotoula
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.